AGENDA

Day 1: August 10

2:00 pm Welcome and Introductions
David P. Nau, PhD, RPh, CPHQ (Chair)
Peter Angood, MD, Senior Advisor, Patient Safety
Heidi Bossley, MSN, MBA, Managing Director, CDP
Andrew Lyzenga, MPP, Project Manager
Elisa E. Munthali, MPH, Project Manager
Eric Colchamiro, MPA, Research Analyst

2:15 pm Project Overview and Measure Evaluation Criteria Review
Andrew Lyzenga

2:30 pm Disclosures of Interest
Ann Hammersmith, JD, General Counsel

2:40 pm Technical Advisory Panel Review
- PSM-009-10: Medication Administration Variance (ASC Quality Collaboration)
- PSM-010-10: Querying and Counseling about Anti-Epileptic Drug (AED) Side-Effects (American Academy of Neurology)

3:40 pm NQF Member/Public Comment

3:45 pm Technical Advisory Panel Review
- PSM-023-10: Patient(s) with hepatitis C infection taking interferon that had periodic serum ALT monitoring (Ingenix, Inc.)
- PSM-024-10: Patient(s) with hepatitis C infection taking interferon that had periodic CBC with differential monitoring (Ingenix, Inc.)
• **PSM-025-10**: Patient(s) with HIV infection taking antiretroviral medications that had a serum ALT or AST test in last 6 reported months (Ingenix, Inc.)

• **PSM-026-10**: Patient(s) with HIV infection taking antiretroviral medications that had a CBC in last 6 reported months (Ingenix, Inc.)

4:45 pm    NQF Member/Public Comment

4:50 pm    Recap

5:00 pm    Adjourn